388 related articles for article (PubMed ID: 24460800)
21. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
22. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
23. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
24. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
[TBL] [Abstract][Full Text] [Related]
25. Managing dyslipidaemia in type 2 diabetes mellitus.
Szalat A; Durst R; Leitersdorf E
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):431-44. PubMed ID: 27432076
[TBL] [Abstract][Full Text] [Related]
26. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Chapman MJ; Le Goff W; Guerin M; Kontush A
Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
[TBL] [Abstract][Full Text] [Related]
27. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
28. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
Gaudet D; Drouin-Chartier JP; Couture P
Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
[TBL] [Abstract][Full Text] [Related]
29. New Era of Lipid-Lowering Drugs.
Barter PJ; Rye KA
Pharmacol Rev; 2016 Apr; 68(2):458-75. PubMed ID: 26983688
[TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
31. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
32. Advances in the management of dyslipidemia.
Kampangkaew J; Pickett S; Nambi V
Curr Opin Cardiol; 2017 Jul; 32(4):348-355. PubMed ID: 28505047
[TBL] [Abstract][Full Text] [Related]
33. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
Rached FH; Chapman MJ; Kontush A
Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
35. [ECS guidelines 2016 - dyslipidaemias].
Sinning D; Landmesser U
Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
[TBL] [Abstract][Full Text] [Related]
36. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
37. Implications for REDUCE IT in clinical practice.
Bittner V
Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
[TBL] [Abstract][Full Text] [Related]
38. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
Watts GF; Karpe F
Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
[TBL] [Abstract][Full Text] [Related]
39. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines.
Lan NSR; Burns K; Bell DA; Watts GF
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):104-113. PubMed ID: 33278128
[TBL] [Abstract][Full Text] [Related]
40. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.
Hermans MP; Valensi P
Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):118-129. PubMed ID: 29493554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
